Abstract: The invention provides novel compounds which are capable of stimulating the proliferation or/and the outgrowth from cells presenting the neural cell adhesion molecule (NCAM). Additionally, the invention relates to methods for treatment of normal, degenerated and damaged NCAM presenting cells.

Abstract: The present invention relates to an improved process for the production of peptides by solid-phase synthesis. The invention also relates to agents which are useful in solid-phase peptide synthesis.

Abstract: The present invention relates to an improved process for the production of peptides by solid-phase synthesis. The invention also relates to agents, which are useful in solid-phase peptide synthesis.

Abstract: The present invention relates to an improved process for the production of peptides by solid-phase synthesis. The invention also relates to agents which are useful in solid-phase peptide synthesis.

Abstract: A novel set of inhibitors of the binding interaction between human urokinase plasminogen activator (uPA) and its cell surface receptor (uPAR) has been developed. The inhibitors comprise of peptide fragments, monomeric or in multiple copies attached to a common scaffold, in which the amino acid sequence may include uncommon substituted amino acids to partially comprise of peptoid sequences. The present invention also relates to the use of such peptides in therapy, in particular for the treatment of cancer, having developed a modified non-human mammalian receptor to which the novel inhibitors are antagonistic.

Abstract: The present invention concerns an NCAM (neural cell adhesion molecule) binding peptide capable of stimulating NCAM signalling and/or interfering with cell adhesion. The compound may be used for the treatment of diseases or conditions of the central and peripheral nervous system.

Abstract: The invention provides novel compounds which are capable of stimulating the proliferation or/and the outgrowth from cells presenting the neural cell adhesion molecule (NCAM). Additionally, the invention relates to methods for treatment of normal, degenerated and damaged NCAM presenting cells.

Abstract: The invention provides novel compounds which are capable to stimulate the proliferation or/and the outgrowth from cells presenting the neural cell adhesion molecule (NCAM). Additionally, the invention relates to pharmaceutical compositions, medicaments and methods for treatment of normal, degenerated and damaged NCAM presenting cells.

Abstract: The present invention relates to a method for preparing a ligand presenting assembly (LPA), an LPA, an immunological composition and a vaccine. The invention further relates to a method for generating antibodies, a kit for use in diagnosis and use of an LPA for preparing a pharmaceutical composition.

Abstract: A diagnostic method is disclosed which utilizes short C-terminal fragments of Borrelia burgdorferi sensu lato derived protein OspC. The 4 amino-terminal acids Pro-Lys-Pro (SEQ ID NO: 22) are shown to be essential in immune reactivity between sera from patients suffering from early borreliosis and various OspC derivatives and it is shown that in order to be effective as a diagnostic agent, 5 consecutive amino acid residues long homologue of a fragment identical to the 10 C-terminal amino acids of OspC (SEQ DI NO: 1). Also disclosed are vaccines utilizing the short peptides as well as methods for their preparation.

Abstract: A diagnostic method is disclosed which utilizes short C-terminal fragments of Borrelia burgdorferi sensu lato derived protein OspC. The 4 amino-terminal acids Pro-Lys-Pro (SEQ ID NO: 22) are shown to be essential in immune reactivity between sera from patients suffering from early borreliosis and various OspC derivatives and it is shown that in order to be effective as a diagnostic agent, 5 consecutive amino acid residues long homologue of a fragment identical to the 10 C-terminal amino acids of OspC (SEQ DI NO: 1). Also disclosed are vaccines utilizing the short peptides as well as methods for their preparation.

Abstract: A combinatorial library composition and method for using the library to construct oligomers effective to bind to a selected ligand is disclosed. The library composition includes at least two sets of ar oligomer libraries, each library set having selected oligomer subunit positions filled by known subunits, and other subunit positions containing permutations of subunits. In the selection method, oligomers from each library set are identified, and a new permutation library formed of subunits corresponding to the highest binding affinity oligomers in each library is screened for binding affinity to the selected ligand.

Abstract: A method for the solid-phase synthesis of peptides or proteins in high yield and high purity uses a solid support consisting of a functionalized polystyrene-grafted polymer substrate, the grafted polystyrene chains being substantially non-cross-linked and having a chain molecular weight, not including optional non-reactive substituents, of at least 200,000, preferably in the range of 600,000-1,200,000. Particularly suitable polymer substrates are substrates of a polyolefin such as polyethylene. The method is particularly well-suited to the compartmentalized synthesis of a multitude of peptides or proteins in a parallel and substantially simultaneous fashion.

Abstract: A method for the solid-phase synthesis of peptides or proteins in high yield and high purity uses a solid-support consisting of a functionalized polystyrene-grafted polymer substrate, the grafted polystyrene chains being substantially non-cross-linked and having a chain molecular weight, not including optional non-reactive substituents, of at least 200,000, preferably in the range of 600,000-1,200,000. Particularly suitable polymer substrates are substrates of a polyolefin such as polyethylene. The method is particularly well-suited to the compartmentalized synthesis of a multitude of peptides or proteins in a parallel and substantially simultaneous fashion.